Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial.

ABSTRACT:

Objective

To assess the efficacy and safety of hydroxychloroquine plus standard of care compared with standard of care alone in adults with coronavirus disease 2019 (covid-19).

Design

Multicentre, open label, randomised controlled trial.

Setting

16 government designated covid-19 treatment centres in China, 11 to 29 February 2020.

Participants

150 patients admitted to hospital with laboratory confirmed covid-19 were included in the intention to treat analysis (75 patients assigned to hydroxychloroquine plus standard of care, 75 to standard of care alone).

Interventions

Hydroxychloroquine administrated at a loading dose of 1200 mg daily for three days followed by a maintenance dose of 800 mg daily (total treatment duration: two or three weeks for patients

SUBMITTER: Tang W 

PROVIDER: S-EPMC7221473 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature